Alejandro Rojas | Immunology Cellular Interactions | Best Researcher Award

Posted on by Cell Biologist

Assist. Prof. Dr. Alejandro Rojas | Immunology Cellular Interactions | Best Researcher Award

Assist. Prof. Dr. Alejandro Rojas | Austral University of Chile | Germany

Dr. Alejandro Alfredo Rojas Fernández is a distinguished Chilean molecular biotechnologist and neuroscientist, currently serving as CEO of Berking Theranostics UG in Hamburg, Germany, and Assistant Professor at the Universidad Austral de Chile. With over two decades of research spanning neurodegeneration, immunology, and viral pathogenesis, Dr. Rojas-Fernández has emerged as a leading expert in molecular diagnostics and theranostics. His innovative work has significantly impacted global health, notably through his contributions to SARS-CoV-2 research and senolytic therapies. A dual academic and entrepreneur, he bridges fundamental science and clinical application, actively publishing in top-tier journals such as Nature Aging, Molecular Psychiatry, and Journal of Cell Biology. Fluent in interdisciplinary collaboration, his efforts have been internationally recognized with multiple honors. With a passion for translational science, Dr. Rojas-Fernández continues to inspire the next generation of biomedical innovators through mentorship and leadership in biotechnology and neuroscience.

Publication Profile:

Orcid

Education:

Dr. Alejandro Rojas-Fernández earned his PhD in Biology from the University of Konstanz, Germany (2006–2010), where his research focused on the regulation of Hdm2/HdmX-mediated ubiquitination and neddylation—mechanisms central to protein stability and cancer biology. Prior to his doctorate, he completed his engineering degree in Molecular Biotechnology (2004–2005) and his B.Sc. in Molecular Biotechnology Engineering (2000–2004) at the Faculty of Sciences, University of Chile—one of Latin America’s leading research institutions. His multidisciplinary education integrates molecular biology, neurobiology, immunology, and translational medicine, equipping him with the foundational and advanced tools to tackle complex biomedical challenges. Dr. Rojas-Fernández’s academic training has been marked by academic excellence and international mobility, enabling him to collaborate and lead research projects across Europe and Latin America.

Experience:

Dr. Rojas-Fernández brings over 20 years of experience in translational biomedical research, academia, and biotech innovation. As CEO of Berking Theranostics UG, he spearheads the development of personalized diagnostic platforms and therapeutics, with a focus on neurodegenerative and inflammatory diseases. In his role as Assistant Professor at Universidad Austral de Chile (20% appointment), he leads the Medical Biotechnology Laboratory within the Centre for Interdisciplinary Studies on the Nervous System (CISNe), contributing to scientific training and cutting-edge research. He previously trained and collaborated at institutions such as the University of Dundee, University of Queensland, and University of Constance, advancing molecular mechanisms of SUMOylation, proteostasis, inflammasome biology, and viral-host interactions. His interdisciplinary expertise allows him to translate complex cellular insights into tangible clinical applications, and his leadership has resulted in high-impact publications, product pipelines, and strategic biotech partnerships in Europe and Latin America.

Awards and Honors:

Dr. Rojas-Fernández has received multiple prestigious honors recognizing his innovative biomedical research. In February 2025, he was named “Innovator of the Month” by Hamburg Invest for groundbreaking biotech contributions in Germany. He was awarded the Medal of the City of Valdivia for his vital role in controlling the SARS-CoV-2 pandemic, one of the highest local honors in Chile. Additionally, he received the 2nd of October Medal for Science and Innovation, recognizing his scientific leadership in Chile’s Los Ríos region. These accolades underscore his impact on global public health, neurodegenerative research, and biotechnology entrepreneurship. His consistent recognition reflects a career dedicated to translational excellence, fostering international collaboration, and advancing science for the benefit of society. His scientific achievements continue to inspire innovation and interdisciplinary approaches within the global scientific community.

Research Focus:

Dr. Alejandro Rojas-Fernández’s research centers on cellular stress responses, ubiquitin/SUMO signaling, neurodegeneration, and host-pathogen interactions. A core focus is the molecular crosstalk between autophagy, protein quality control, and inflammasome activation in brain and immune cells. He has made significant advances in understanding the effects of SARS-CoV-2 on microglia, mechanisms of senescence in aging brains, and nanobody-based viral neutralization. His studies also explore the intersection of endoplasmic reticulum stress and neurodegenerative pathways, using high-content screening and proteomics to uncover therapeutic targets. He actively translates molecular insights into diagnostics and theranostic tools, positioning him at the forefront of personalized medicine. As CEO of a biotech startup, he is developing platforms that integrate biomarker discovery with AI for neuroinflammation profiling. His research bridges fundamental biology and clinical applications, promoting innovative therapies for Alzheimer’s, Parkinson’s, cancer, and viral infections.

Publications Top Notes: 

  1. Negative Modulation of Macroautophagy by Stabilized HERPUD1… – Front Cell Dev Biol, 2022

  2. SARS-CoV-2 drives NLRP3 inflammasome activation in human microglia… – Mol Psychiatry, 2022

  3. The p97/VCP segregase is essential for arsenic-induced degradation of PML… – J Cell Biol, 2023

  4. Lack of Parkinsonian Pathology after Proteasome Inhibitor Injection… – Front Aging Neurosci, 2021

  5. NSPA modulates postsynaptic NMDAR stability… – BMC Biol, 2020

  6. Role of PSMD14 in Golgi-to-ER transport and APP processing – Cells, 2020

  7. WDR90 in NLRC4 inflammasome and Salmonella resistance – Dev Comp Immunol, 2019

  8. Proteomic identification of APC interaction partners – Mol Cancer Res, 2019

  9. DHX15 regulates CMTR1-dependent gene expression – Life Sci Alliance, 2018

  10.  Membrane ruffling by polarized stim1 and orai1 – Sci Reports, 2017

Conclusion:

Dr. Alejandro Alfredo Rojas Fernández stands out as a pioneering researcher who consistently delivers scientifically rigorous, socially impactful, and clinically relevant work. His career spans critical sectors—basic research, applied biotechnology, and public health—making him a model example of the translational scientist. With accolades from both European and Latin American institutions and a track record of high-impact publications, Dr. Rojas exemplifies what it means to be a globally relevant and community-driven scientist. His work during the COVID-19 pandemic, innovations in molecular neuroscience, and leadership in therapeutic biotechnology underscore his immense value to the global research community. In conclusion, he is not only a suitable but a highly deserving candidate for the Best Researcher Award.

Herbeuval Jean-Philippe | Immunology Cellular Interactions | Best Innovator Award

Posted on by Cell Biologist

Dr. Herbeuval Jean-Philippe | Immunology Cellular Interactions | Best Innovator Award

Dr. Herbeuval Jean-Philippe | CNRS | France

Jean-Philippe Herbeuval is a French immunologist and CNRS Director of Research, renowned for pioneering contributions to translational immunology and biomedical innovation. A PhD holder in immuno-oncology, he completed a prestigious Fogarty Fellowship at the NIH, USA, where he earned the Norman P. Salzman Award. He founded and leads the CBMIT team at Université Paris Cité, integrating immunology, virology, and chemistry for therapeutic discovery. Herbeuval has launched two biotech companies: Ermium Therapeutics, based on anti-interferon therapies, and Elyris Pharma, centered on PDK1 as a novel anti-inflammatory target. With 9 patents (3 licensed), €8.8M in research funding, and >70 publications (h-index 28), his innovations span diagnostics to therapeutics. He also contributes to policy and innovation strategy through national and international committees. Recognized for his vision, leadership, and mentorship, Herbeuval exemplifies the intersection of academic research and impactful biotechnology entrepreneurship.

Publication Profile:

Google Scholar

✅ Strengths for the Award:

  1. Exceptional Innovation in Immunology & Therapeutics

    • Discovered key therapeutic targets such as CXCR4 and PDK1.

    • Founded Ermium Therapeutics (2019) and Elyris Pharma (2024), securing over €12M in funding.

    • Holds 9 patents, with 3 already licensed — a key indicator of translational success.

  2. Proven Scientific Leadership

    • Director of Research (CNRS), Head of CBMIT at Université Paris Cité.

    • Established and led multiple interdisciplinary research teams and platforms (Cyto2BM, CBMIT).

    • Supervised 10 PhD students, 7 postdocs, and over 18 master’s students, many of whom reached elite positions.

  3. High-Impact Research Output

    • 70+ publications, including high-citation studies on interferon signaling in HIV.

    • Over 3,500 citations, h-index: 28 — showing strong impact and visibility.

  4. Strong National and International Recognition

    • Winner of the prestigious i-Lab National Innovation Prize (France, 2019).

    • Invited speaker at over 24 international conferences; reviewer for Nature Medicine and PNAS.

    • Advisor for funding agencies across the US (NIH), UK (MRC), China, and Brazil.

  5. Valuable Public and Government Engagement

    • CNRS Innovation Ambassador (2024) and expert for multiple national programs (ANRS, Campus France).

    • Actively engages in public science communication (TV, radio, press).

🔧 Areas for Improvement:

  1. Scaling Global Industry Impact

    • While Ermium and Elyris are high-potential, further proof of market adoption and therapeutic success will solidify his innovation leadership globally.

  2. Broader Patent Commercialization

    • More patents could potentially be moved from licensing to full-scale clinical trials or product development phases.

  3. Diversity of Therapeutic Areas

    • While the focus on interferon biology and immunomodulation is powerful, broader expansion into other disease domains (e.g., neuroinflammation, metabolic syndromes) could enhance reach.

🎓 Education:

Jean-Philippe Herbeuval earned his PhD in immuno-oncology in 2001 from Université Jean Monnet, Saint-Étienne, working under the INSERM network. He then pursued a highly competitive five-year Fogarty Postdoctoral Fellowship at the National Institutes of Health (NIH), USA, under Dr. Gene Shearer, focusing on the antiviral response to HIV. During this time, he earned multiple prestigious awards including the Norman P. Salzman Award and an NIH Young Scientist Cash Award. Upon returning to France, he secured a CNRS Junior PI position in 2006 and received his Habilitation to Direct Research (HDR) in 2008 from Université Paris Descartes. His rapid career progression continued with his appointment as Director of Research (2nd class) in 2013 and promotion to 1st class in 2019 at CNRS UMR8601. His educational path reflects an exceptional blend of scientific rigor, international exposure, and leadership in innovation.

💼 Experience:

Jean-Philippe Herbeuval brings over two decades of distinguished experience at the interface of academic research and biotech innovation. Starting with his postdoctoral fellowship at NIH (2001–2006), he led groundbreaking studies on interferon responses in HIV. Since 2006, he has served within CNRS, creating and leading the CBMIT interdisciplinary team. He established the Cyto2BM core facility and spearheaded multiple translational projects. As scientific founder of Ermium Therapeutics (2019) and Elyris Pharma (2024, in progress), he has successfully attracted venture capital and secured technology transfer agreements. His strategic involvement extends to national innovation committees (ANRS, CNRS, Campus France) and advisory roles. He has trained over 35 researchers and supervised major national/international grants. Notably, he combines deep scientific insight with an entrepreneurial mindset, as shown by his participation in Deeptech Founders and RISE programs. His experience spans leadership, translational science, investment negotiations, and scientific mentoring.

🔬 Research Focus:

Jean-Philippe Herbeuval’s research is centered on translational immunology, particularly type I interferons, autoinflammatory pathways, and host-pathogen interactions. His work explores immune dysregulation in infectious diseases such as HIV, SARS-CoV-2, dengue, and influenza, with a special focus on the immune-modulatory roles of dendritic cells and apoptotic pathways. He has identified novel therapeutic targets including CXCR4 and PDK1, leading to two biotech start-ups and multiple patents. His interdisciplinary CBMIT team integrates immunology, virology, medicinal chemistry, and computational modeling to develop innovative therapeutic strategies and biomarkers. He has a keen interest in immunomodulation, therapeutic interference with IFN pathways, and discovery of druggable checkpoints in innate immunity. With over 70 peer-reviewed publications, his scientific output has shaped current understanding of immune pathogenesis and opened new avenues for therapy in inflammatory and infectious diseases. His approach bridges fundamental research with practical applications in drug discovery and biotech development.

📚 Publications Top Notes:

  1. 🧬 HIV inhibits CD4+ T-cell proliferation by inducing indoleamine 2,3-dioxygenase in plasmacytoid dendritic cells

  2. ⚰️ CD4+ T-cell death induced by infectious and noninfectious HIV-1: role of type 1 interferon–dependent, TRAIL/DR5-mediated apoptosis

  3. 🚻 Sex differences in plasmacytoid dendritic cell levels of IRF5 drive higher IFN-α production in women

  4. 🧪 HIV-1 immunopathogenesis: how good interferon turns bad

  5. 🔄 Regulation of indoleamine 2,3-dioxygenase and tryptophanyl-tRNA-synthetase by CTLA-4-Fc in human CD4+ T cells

  6. 🧠 Differential expression of IFN-α and TRAIL/DR5 in lymphoid tissue of progressor vs. nonprogressor HIV-1-infected patients

  7. 🧟 HIV turns plasmacytoid dendritic cells into TRAIL-expressing killer pDC via TLR7-induced IFN-α

  8. 🧬 Regulation of TRAIL on primary CD4+ T cells by HIV-1: role of plasmacytoid dendritic cells

  9. 💉 TRAIL in HIV-1–infected patients and its production by antigen-presenting cells

  10. 🧫 Recruitment of STAT3 for production of IL-10 by colon carcinoma cells induced by macrophage-derived IL-6

🧾 Conclusion:

Dr. Jean-Philippe Herbeuval stands out as a highly qualified and deserving candidate for the Best Innovator Award. His rare combination of scientific excellence, translational innovation, entrepreneurial leadership, and mentorship places him in the top tier of biomedical innovators. His work not only bridges science and industry but also directly contributes to addressing global health challenges. Continued support and recognition of his efforts will likely catalyze further innovation in therapeutic immunology.

Miriam Götte | Immunology Cellular Interactions | Best Researcher Award

Posted on by Cell Biologist

Assist. Prof. Dr. Miriam Götte | Immunology Cellular Interactions | Best Researcher Award

Assist. Prof. Dr. Miriam Götte , Westdeutsches Tumorzentrum, Universitätsklinikum Essen , Germany

Dr. Miriam Götte is a leading expert in exercise and movement science in oncology, currently affiliated with the University Hospital Essen. With a dedicated focus on pediatric and young adult cancer care, she has led numerous interdisciplinary initiatives combining sports science, immunology, and oncology. As head of the Working Group on Sports and Movement Therapy at the West German Tumor Center, she has pioneered therapeutic interventions improving the quality of life in cancer patients. Dr. Götte holds a habilitation in Movement Science in Oncology and has been a postdoctoral researcher since 2014. Her work has been recognized nationally and internationally through prestigious awards. Passionate about improving survivorship care, she integrates clinical research, physical rehabilitation, and academic leadership. Alongside her academic career, she balances motherhood, having taken two parental leaves, which reflects her ability to manage demanding roles in both personal and professional spheres.

Publication Profile:

Scopus

✅ Strengths for the Award:

  1. 🌍 Leading Expertise in Exercise Oncology: Dr. Götte has made outstanding contributions to the field of exercise-based interventions in pediatric and adolescent oncology, a highly impactful and emerging research domain.

  2. 📊 Rich and Relevant Research Output: With over 10 peer-reviewed publications in top-tier journals (2023–2024 alone), she is actively contributing novel data, especially around HIIT, immune response, stem cell transplantation, and survivorship care.

  3. 👩‍🔬 Translational Focus with Real-World Impact: Her work bridges clinical research and applied therapy, ensuring that findings benefit patient quality of life and recovery during and after cancer treatment.

  4. 🤝 National Leadership and Collaborations: As Head of the Working Group on Sports and Movement Therapy and a core member of the ActiveOncoKids Network, she leads national initiatives and cross-border collaborations.

  5. 🏆 Recognized with Prestigious Awards: Awards such as the MASCC Young Investigator Award (2015) and Best Abstract at ASORS (2017) reflect her high academic standing and the relevance of her research.

  6. 📚 Interdisciplinary Approach: Combining sports science, immunology, pediatrics, and education, she exemplifies a multidisciplinary perspective that advances both research and therapeutic care.

⚙️ Areas for Improvement:

  1. 📣 Global Visibility: While well-known in German-speaking countries and European forums, increasing participation in global oncology or exercise medicine symposia (e.g., ASCO, ACSM) would raise international recognition.

  2. 💼 Expanded Mentorship: Publishing with more junior researchers as first authors could further support the next generation and solidify her legacy as a mentor in her field.

  3. 🌐 Broader Public Engagement: Developing online modules, webinars, or patient-facing tools (especially for young survivors) could enhance public awareness and dissemination of her impactful work.

🎓 Education:

Dr. Miriam Götte has a solid academic background in sports and medical sciences. She began her academic journey studying Sports Science with a focus on prevention and rehabilitation at the University of Cologne from 2006 to 2010. During this period, she also pursued studies in Educational Sciences. She advanced to a doctoral program in Medical Sciences at the University of Duisburg-Essen, completing it between 2010 and 2014 under the mentorship of Prof. Dr. Dirk Reinhardt. Her academic accomplishments culminated in a habilitation in “Movement Science in Oncology” at the Medical Faculty of the University of Duisburg-Essen in 2022. This advanced qualification marks her as an expert in the interplay of exercise and oncology, particularly for pediatric and adolescent populations. Her academic path has been underpinned by a strong interdisciplinary approach, combining sports science, oncology, and education to support patients holistically.

💼 Experience:

Dr. Götte’s professional journey began at the Department of Pediatrics III, University Hospital Essen, where she worked from 2010 to 2014 during her doctoral training. She later became head of Sports and Exercise Therapy at the West German Tumor Center (2014–2017) and continued in leadership roles at the same institution until July 2023. Since January 2023, she has served as head of the Working Group on Sports and Movement Therapy in Oncology, playing a pivotal role in the ActiveOncoKids Center Ruhr. Dr. Götte also coordinated teacher training modules in Spanish and led national collaborations to develop exercise strategies during cancer treatment. She has taken two parental leaves (2017–2018 and 2023–2024), highlighting her balance between research and personal life. Her hands-on leadership in multi-center projects and her dedication to integrating physical activity into oncology care make her a driving force in supportive cancer therapy.

🏆 Awards and Honors:

Dr. Miriam Götte has received numerous awards recognizing her impactful research and leadership. She was honored with the Young Investigator Award of the Year at the MASCC/ISOO Annual Meeting on Supportive Care in Cancer in 2015. Her work on adolescent cancer care earned the Best Abstract Award at the 5th ASORS Congress in 2017. She was selected for the prestigious Josepha and Charlotte von Siebold Habilitation Support Program (2018–2019), and later received support from the Corona Care in Medicine Program (2020–2021) by the Medical Faculty of the University of Duisburg-Essen. These accolades underline her academic excellence and leadership in movement science and oncology. Dr. Götte’s pioneering research continues to shape exercise-based cancer therapy, especially for children and adolescents, earning her national and international recognition as a forward-thinking clinician-scientist.

🔬 Research Focus:

Dr. Miriam Götte’s research revolves around exercise oncology, with a strong emphasis on pediatric and adolescent cancer patients. Her primary interest lies in exploring how physical activity interventions, particularly high-intensity interval training (HIIT), influence immune function, physical fitness, and quality of life during and after cancer therapy. She investigates the physiological and psychological impacts of exercise throughout different treatment phases, including stem cell transplantation. Her work contributes significantly to the emerging field of supportive oncology, where movement-based interventions are tailored to patient needs. Dr. Götte is also a central figure in the ActiveOncoKids network, enhancing access to structured physical activity across German-speaking countries. With a translational approach, her research bridges clinical care, immunological assessments, and rehabilitative exercise programs. Her focus is not only scientific but also deeply patient-centered, advocating for movement as a form of healing and empowerment in cancer survivorship.

📚 Publications Top Notes:

  1. 🏋️‍♂️ High-Intensity Interval Training Boosts Immune Cells in Advanced Cancer Patients and Healthy Controls – Cancer Medicine (submitted)

  2. 🧬 Impact of a Single HIIT Session on NK Cells and ILCs in Adolescents Undergoing Cancer Treatment – BMC Cancer (minor revision)

  3. 🌟 YOUEX: Longitudinal Effects on Quality of Life in Young Adults with Cancer – JAYAO (submitted)

  4. 💪 Low vs. Moderate Intensity Exercise in Pediatric Allo-HSCT Recovery – ANIMAL – Pediatric Blood & Cancer (submitted)

  5. 👶 Physical Activity Behaviors in Childhood Cancer Survivors – J Cancer Survivorship (2024)

  6. 🧒 ActiveOncoKids: Centralized Physical Activity Counseling During Oncology – Klinische Pädiatrie (2024)

  7. 🏃 Severely Reduced Physical Performance at Stem Cell Transplant Admission – BMJ Open Sport Exerc Med (2024)

  8. 🧘 P-move: RCT of Exercise in Pancreatic or Biliary Tract Cancer – Supportive Care in Cancer (2024)

  9. 🌿 Exercise Therapy in Oncology: Impact on Quality of Life and Side Effects – Dtsch Arztebl Int (2024)

  10. 🧑‍⚕️ Adaptation of Pediatric Exercise Programs During COVID-19 in Germany – Frontiers in Pediatrics (2024)

🧾 Conclusion:

Dr. Miriam Götte is highly suitable and deserving of the Best Researcher Award. Her focused and prolific research on the role of physical activity in pediatric and adolescent oncology, combined with her leadership in clinical and academic settings, sets her apart as a pioneer in supportive cancer care. She demonstrates a rare combination of scientific rigor, patient-centeredness, and organizational leadership. With strategic expansion of her international visibility and mentoring activities, she is positioned to become one of the global leaders in exercise oncology.